AbbVie Sees 2014 Approval of Hepatitis Drugs, Shares Rise

Published February 5, 2014

AbbVie sees 2014 approval of hepatitis drugs, shares rise
(Reuters) – AbbVie Inc issued a cautious 2014 profit forecast, but said it expects U.S. approval this year for its potentially lucrative new all-oral treatment for hepatitis C, sending its shares up 3.4 percent. The company, before releasing fourth …
Read more on Reuters

Hepatitis C treatment shifts as new drugs emerge
John Billeris has tried and failed four grueling rounds of treatment for his chronic hepatitis C infection over the past 15 years. He is not convinced that his fifth try — with what he jokingly calls "magic medicine" — will be the charm. But he says …
Read more on USA TODAY

New Breast Cancer Drug Could Transform Treatment
Pfizer announced today a successful phase 2 trial of its breast cancer drug Palbociclib, which had shares up 2.5% on the news. "We are delighted with the final data, which suggests the potential for Palbociclib to transform the standard of care …
Read more on DailyFinance

More Drug Treatment News 2014 Information…